NCT01023256View on ClinicalTrials.gov

Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Rheumatoid Arthritis
Interventions
DRUG

MOR103

MOR103 0.3 mg/kg or placebo iv x 4 doses

DRUG

MOR103

MOR103 1.0 mg/kg or placebo iv x 4 doses

DRUG

MOR103

MOR103 1.5 mg/kg or placebo iv x 4 doses

Trial Locations (5)

Unknown

MorphoSys Investigative sites, MorphoSys Investigative Sites

MorphoSys Investigative sites, MorphoSys Investigative Sites

MorphoSys Investigative sites, MorphoSys Investigative Sites

MorphoSys Investigative sites, MorphoSys Investigative Sites

MorphoSys Investigative sites, MorphoSys Investigatíve Sites

Sponsors

Lead Sponsor

MorphoSys AG
All Listed Sponsors
lead

MorphoSys AG

INDUSTRY

NCT01023256 - Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter